and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Specification:

Please substitute the following paragraph beginning on page 1, line 4, for the pending paragraph:

This application is a continuation-in-part of U.S. Appl. No. 09/218,444, filed December 22, 1998, now U.S. Patent No. 6,238,888, issued May 29, 2001, and claims the benefit of priority of the filing date of U.S. Appl. Nos. 60/068,493 filed on December 22, 1997, abandoned, 60/137,448, filed June 2, 1999, abandoned and 60/160,913, filed October 22, 1999, abandoned; the disclosures of all of which are incorporated by reference herein.

Please substitute the following paragraph beginning on page 27, line 1, for the pending paragraph:

KGF-2 stimulates the proliferation of epithelial cells and epidermal keratinocytes but not mesenchymal cells such as fibroblasts. Thus, "a polypeptide having KGF-2 protein-like activity" includes polypeptides that exhibit the KGF-2 activity, in the keratinocyte proliferation assay set forth below and U.S. Application No. 08/910,875, abandoned, and can bind to the FGF receptor isoforms 1-iiib and 2-iiib. Although the degree of activity need not be identical to that of the KGF-2 protein, preferably, "a polypeptide having KGF-2 protein-like activity" exhibits substantially similar activity as compared to the KGF-2 protein (i.e., the

a2

candidate polypeptide exhibits greater activity or not more than tenfold less and, preferably, not more than about twofold less activity relative to the reference KGF-2 protein).

Please substitute the following paragraph beginning on page 44, line 27, for the pending paragraph:

a3

Further KGF-2 polypeptides are described in PCT/US95/01790, filed February 14, 1995, abandoned, and U.S. Appl. Nos. 08/461,195, filed June 5, 1995, abandoned, 08/696,135, filed August 13, 1996, abandoned, 60/023,852, filed August 13, 1996, abandoned, 60/039,045, filed February 28, 1997, abandoned, 08/862,432, filed May 23, 1997, abandoned, 60/055,561, filed August 13, 1997, abandoned, 08/910,875, filed August 13, 1997, abandoned, 09/023,082, filed February 13, 1998, now U.S. Patent No. 6,077,692, issued June 20, 2000, 09/345,373, filed July 1, 1999, pending, 60/142,343, filed July 2, 1999, abandoned, 60/143,648, filed July 14, 1999, abandoned, 60/144,024, filed July 15, 1999, abandoned, 60/148,628, filed August 12, 1999, abandoned, 60/149,935, filed September 24, 1999, abandoned, 60/163,375, filed November 3, 1999, abandoned, 60/171,677, filed December 22, 1999, abandoned, and 60/198,322, filed April 19, 2000, abandoned, the disclosures of all of which are incorporated by reference herein.

Please substitute the following paragraph beginning on page 45, line 15, for the pending paragraph:

a4

KGF-2 is useful for treating a number of diseases and conditions. For example, KGF-2 is active *in vitro* and *in vivo* in various wound healing models. See, U.S. Application Nos.

a4 08/910,875, filed August 13, 1997, abandoned, and 09/023,082 filed February 13, 1998, now U.S. Patent No. 6,077,692, issued June 20, 2000.

Please substitute the following paragraph beginning on page 47, line 15, for the pending paragraph:

A number of other indications that can be treated by the composition of the present invention are described in U.S. Application Nos. 08/910,875, abandoned, and 09/023,082, a5 now U.S. Patent No. 6,077,692, issued June 20, 2000, and are herein incorporated by reference.

Please substitute the following paragraph beginning on page 48, line 3, for the pending paragraph:

Other therapeutic uses of KGF-2 are described in U.S. Appl. Nos. 60/074,585, filed February 13, 1998, abandoned, 60/114,484, filed December 30, 1998, abandoned, and a6 09/248,998, filed February 12, 1999, pending, the disclosures of all of which are incorporated by reference herein.

Please substitute the following paragraph beginning on page 50, line 9, for the pending paragraph:

Deletion mutants were constructed from the 5' terminus and 3' terminus of KGF-2 gene using an optimized KGF-2 construct as a template. The deletions were selected based on a7 regions of the gene that might negatively affect expression in E. coli. For the 5' deletion the primers listed below were used as the 5' primer. These primers contain the indicated

restriction site and an ATG to code for the initiator methionine. The KGF-2 (FGF-12) 208 amino acid 3' HindIII primer was used for the 3' primer. PCR amplification for 25 rounds was performed using standard conditions. The products for the KGF-2 36aa/208aa deletion mutant were restricted BspHI for the 5' site and HindIII for the 3' site and cloned into the pQE60 which has bee digested with BspHI and HindIII. All other products were restricted with NcoI for the 5' restriction enzyme and HindIII for the 3' site, and cloned into the pQE60 which had been digested with NcoI and HindIII. For KGF-2 (FGF-12), 36aa/153aa and 128aa 3' HindIII was used as the 3' primer with FGF-12 36aa/208aa as the 5' primer. For FGF-12 62aa/153aa, 128aa 3' HindIII was used as the 3' primer with FGF-12 62aa/208aa as the 5' primer. The nomenclature of the resulting clones indicates the first and last amino acid of the polypeptide that results from the deletion. For example, KGF-2 36aa/153aa indicates that the first amino acid of the deletion mutant is amino acid 36 and the last amino acid is amino acid 153 of KGF-2. The construction of these KGF-2 deletion mutants are also described in U.S. Application Nos. 08/910,875, abandoned, and 09/023,082, now U.S. Patent No. 6,077,692, issued June 20, 2000, and are herein incorporated by reference. Further, as indicated in below, each mutant has N-terminal Met added thereto. However, the KGF-2 deletion polypeptides used in the formulations according to the present invention may or may not have the N-terminal methionine, preferably the polypeptide will be lacking the N-terminal methionine.

a7

In the Claims:

Please cancel claims 8, 34, 35 and 67-70 without prejudice to or disclaimer of the subject matter contained therein.